AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie is presented as the preferred 2026 pharmaceutical investment after FY2025 revenue rose 8.6% to nearly $61.2B and free cash flow reached about $17.8B, supported by growth in Skyrizi, Rinvoq and neuroscience. Bristol Myers Squibb generated higher net income of roughly $7.1B on $48.2B of revenue, but sales declined 0.2% and the company faces patent-expiry, execution and litigation risks, including a revived $6.7B Celgene acquisition lawsuit. BMY is materially cheaper at 9.2x forward P/E and 2.7x sales versus AbbVie's 18.5x and 7.5x, but the article favors AbbVie for its clearer post-Humira growth trajectory.

Analysis

The relevant relative-value question is not growth versus value, but the market’s confidence in each company’s post-cliff earnings floor. ABBV’s premium can persist if its newer franchises convert revenue growth into durable operating leverage; however, the stock has little room for a simultaneous immunology slowdown and IRA-related price reset. BMY’s discount embeds a more severe erosion path, making incremental evidence of replacement-product uptake disproportionately valuable to the multiple even before consolidated growth inflects.

Over the next 1-3 months, the cleaner catalyst is guidance quality: ABBV needs to demonstrate that growth is not being bought through elevated commercial spend or deal activity, while BMY needs evidence that newer brands are offsetting legacy-product declines on an organic basis. BMY’s legal and manufacturing issues matter less as isolated charges than as signals that management may need to preserve cash, reducing flexibility for business development or accelerated shareholder returns. For ABBV, distributor concentration is a working-capital and channel-inventory risk rather than a demand thesis; a wholesaler destock could create a noisy quarterly miss even if prescriptions remain intact.

Consensus likely overstates the simplicity of ABBV as the "safe" choice and understates BMY’s asymmetric rerating potential. At 9.2x forward earnings, BMY does not require a return to meaningful top-line growth to work; stabilization in the erosion rate, credible cost containment, and no further litigation escalation could support multiple expansion. Conversely, ABBV’s 18.5x forward multiple requires continued execution, so the relative trade is vulnerable if immunology growth normalizes faster than expected.

CYTK is a second-order watch rather than a standalone recommendation: any adverse patent or commercial-resolution development could affect BMY’s strategic optionality and litigation overhang. Separately, MCK, COR, and CAH are largely insulated from manufacturer-specific product cycles, but they could benefit modestly from higher specialty-drug throughput; this is unlikely to be material enough to trade absent volume or margin guidance revisions.

Key Decisions for Investors

• Initiate a 3-6 month market-neutral pair: long BMY / short ABBV in equal dollar amounts. The setup targets BMY multiple normalization and/or ABBV premium compression; reassess if BMY’s new-product growth fails to narrow legacy erosion over two reporting periods, or if ABBV again raises full-year guidance on accelerating franchise demand.
• For directional healthcare exposure, avoid adding ABBV before the next earnings print unless prescription-trend data confirm continued immunology momentum. A guidance raise accompanied by stable selling-expense ratios supports a long; a revenue beat driven by inventory, acquisitions, or higher commercialization spend is a reason to fade the initial move.
• Treat BMY as a catalyst watch for the next two earnings cycles rather than a passive value position. Add only on independently verifiable evidence of improving organic growth and sustained free-cash-flow coverage of dividends and debt service; a material adverse Celgene litigation ruling or another manufacturing disruption invalidates the rerating thesis.
• Set an event alert on CYTK/BMY patent and litigation updates. Do not position in CYTK solely on the dispute: the missing inputs are claim scope, timing, and commercial exposure, but a settlement or unfavorable ruling could change BMY’s risk premium quickly.